Ticker Symbol: NLTX
Neoleukin Therapeutics Inc
$6.07 - 20-12-2024 4 p.m. ET
Exchange: NASDAQ
Currency:
USD
Asset
Type: Common Stock
CIK:0001404644
Company Profile
Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Neoleukin's lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface.
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: N/A
Website: www.neoleukin.com
CEO: N/A
Tags:
- Health Technology
- Biotechnology
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Pricing
Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $4.07
Change:
$0.05
(
1.24%)
Days Range: $3.94 - $4.07
Beta: 0.44
52wk. High: $4.70
52wk. Low: $1.88
Ytd. Change 59.20%
50 Day Moving Average: $3.82
200 Day Moving Average: $3.89
Shares Outstanding: 44021429
Valuation
Market Cap: 17.9B
PE Ratio: -
EPS (TTM): 0
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A